ADVM

Adverum Biotechnologies Inc

Healthcare


Presented:12/05/2017
Price:$3.05
Cap:$0.13B
Current Price:$7.69
Cap:$0.16B

Presented

Date12/05/2017
Price$3.05
Market Cap$0.13B
Ent Value$0.03B
P/E RatioN/A
Book Value$4.16
Div Yield0%
Shares O/S43.38M
Ave Daily Vol322,962
Short Int1.40%

Current

Price$7.69
Market Cap$0.16B
Adverum Biotechnologies, Inc. is a clinical-stage biotechnology company that engages in the development of novel gene therapies to treat patients with sight-threatening ophthalmic diseases. It focuses on treatment of wet age-related macular degeneration, alpha-1 antitrypsin deficiency, hereditary angioedema, friedreich's ataxia, severe allergy, color vision deficiency, and juvenile x-linked retinoschisis. The company was founded by Mark S. Blumenkranz, Thomas W. Chalberg, Jr. and Steven Daniel Schwartz on July 17, 2006 and is headquartered in Menlo Park, CA.

Publicly traded companies mentioned herein: Adverum Biotechnologies Inc (ADVM), CSL Ltd (CSL AU), Regenxbio Inc (RGNX), Shire PLC (SHPG; SHP LN)

Highlights

The presenter is long shares of Adverum Biotechnologies (ADVM; $3/ share), a ~$135mm market cap company focused on the development of gene therapies for Alpha-1 Antitrypsin (A1AT) Deficiency, Hereditary Angioedema (HAE), and Wet Age-Related Macular Degeneration (wAMD). In May 2016, Avalanche and Annapurna were combined in a previously announced transaction and Adverum was formed (ADVM began trading on May 12, 2017). A new management team - led by President & CEO Dr. Amber Salzman, and Chairman Paul Cleveland - is overseeing the company following the downfall of Avalanche; and with ~$185mm in cash on its balance sheet, and three viable gene therapy products in the pipeline, the risk/ reward is highly skewed in bulls’ favor. In the presenter’s opinion, ADVM’s three programs could be worth as much as $5bn each, for a total value of $15bn in a “blue sky”/ best case scenario.

  • Signing up and creating account with us unlocks this content for you. Contact us today for full access to DeMatteo Research and more.

  • Signing up and creating account with us unlocks this content for you. Contact us today for full access to DeMatteo Research and more.

Request access to DeMatteo Research for full access

Request Access

Already have an account?

Idea Discussion

Commentor 1 - 2 weeks ago

Signing up and creating account with us, unlocks this content for you. Contact us today for full access to DeMatteo Research and more.

Commentor 1 - 2 weeks ago

Signing up and creating account with us, unlocks this content for you. Contact us today for full access to DeMatteo Research and more.

Idea Discussions display submitted commentary from our investor community.

To read and participate in the discussion with the presenter and investor base, request access to DeMatteo

Request Access

Already have an account?

An error occurred loading this content. Try again later or contact us.